Please login to the form below

Not currently logged in

Xarelto scoops innovation award

Bayer Schering's treatment for the prevention of venous thromboembolism (VTE), was awarded the Innovation award at the UK Prix Galien Awards

Bayer Schering's treatment for the prevention of venous thromboembolism (VTE), Xarelto (rivaroxaban) was awarded the Innovation award at this year's UK Prix Galien Awards ceremony, hosted on October 13 by Lord Walton of Detchant at the House of Lords in London.

Bayer team photo
Bayer Schering team


The second awards category, for Orphan Drugs, was won by Shire for Firazyr (icatibant), the first subcutaneous injection indicated for symptomatic treatment of acute attaches of hereditary angioedema (HAE).

Secretary of State for Health, Andrew Lansley, presented a keynote address in which he stated that he was determined that government would not only secure reform in the NHS, but also reform that promoted innovation in the pharmaceutical industry.

"Our objective is to build an NHS that is going to assess outcomes. If the pharmaceutical industry can deliver innovation – and these Prix Galien awards have repeatedly demonstrated that it can – we will all see the reward that comes from it," Andrew Lansley said.

He continued: "The pharmaceutical industry is instrumental to how we deliver better healthcare and a growing economy in the future. I want to stimulate that. If we are going to do that then we need to be thinking about promoting innovation all the way through the system."


Shire team
Shire team


According to chairman of the judging panel, Professor Sir Michael Rawlins: "The Prix Galien is about honouring excellence in pharmaceutical research and development. It is about recognising the contribution that new medicines can make to the lives of people with life-threatening conditions."

The 2010 UK Prix Galien comprised a total of 10 shortlisted products: Erbitus (cetuximab, Merck Serono), Iressa (gefitinib, AstraZeneca), RoActemra (tocilizumab, Roche and Chugai), Targinact (oxycodone/naloxone, Napp), Valdoxan (agomelatine, Servier) and Xarelto (Bayer) in the Innovation category, and Afinitor (everolimus, Novartis), Firazyr (Shire), Mozobil (plerixafor, Genzyme) and Vidaza (azacitidine, Celgene) in the Orphan Drug category. Prof Sir Michael commented that the judges had been "immensely impressed" by the standard of the entries this year as well as the creativity, innovation and scientific rigour that had gone into all the shortlisted medicines.

Speaking about Xarelto, Prof Sir Michael said: "This drug has the potential to revolutionise the way thrombotic conditions will be managed in the future. The jury were impressed by the novelty of its pharmacology, by the quality of its clinical development and by the prospects it holds for the future. The prospect of the disappearance of warfarin clinics will be welcomed by physicians, patients and their families."

The UK Prix Galien is organised and managed every two years by specialist market access consultancy WG Consulting, which owns the UK franchise. They remain the only awards of their kind to be judged completely independently of the pharmaceutical industry by senior, well-respected NHS professionals.

14th October 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...